280 related articles for article (PubMed ID: 23511300)
1. Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?
van Hal SJ; Fowler VG
Clin Infect Dis; 2013 Jun; 56(12):1779-88. PubMed ID: 23511300
[TBL] [Abstract][Full Text] [Related]
2. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
3. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
[TBL] [Abstract][Full Text] [Related]
4. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
Mirza HC; Sancak B; Gür D
Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations - results of a prematurely terminated study.
Kalimuddin S; Chan YFZ; Phillips R; Ong SP; Archuleta S; Lye DC; Tan TT; Low JGH
Trials; 2018 Jun; 19(1):305. PubMed ID: 29859132
[TBL] [Abstract][Full Text] [Related]
6. The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia.
Honda H; Doern CD; Michael-Dunne W; Warren DK
BMC Infect Dis; 2011 Dec; 11():335. PubMed ID: 22142287
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
[TBL] [Abstract][Full Text] [Related]
8. Predicting high vancomycin minimum inhibitory concentration isolate infection among patients with community-onset methicillin-resistant Staphylococcus aureus bacteraemia.
Chen SY; Hsueh PR; Chiang WC; Huang EP; Lin CF; Chang CH; Chen SC; Chen WJ; Chang SC; Lai MS; Chie WC
J Infect; 2014 Sep; 69(3):259-65. PubMed ID: 24797078
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: study protocol for a phase IIB randomized controlled trial.
Kalimuddin S; Phillips R; Gandhi M; de Souza NN; Low JG; Archuleta S; Lye D; Tan TT
Trials; 2014 Jun; 15():233. PubMed ID: 24943129
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant
Ozmen Capin BB; Tekeli A; Karahan ZC
Microb Drug Resist; 2020 Mar; 26(3):238-244. PubMed ID: 31545160
[No Abstract] [Full Text] [Related]
11. [Investigation of antibiotic resistance patterns and reduced vancomycin susceptibilities of methicillin-resistant Staphylococcus aureus isolates: a multi-center study].
Çıkman A; Aydın M; Gülhan B; Parlak M; Gültepe B; Kalaycı Y; Bayındır Bilmen F; Solmaz S; Özekinci T
Mikrobiyol Bul; 2015 Apr; 49(2):240-8. PubMed ID: 26167824
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years.
Musta AC; Riederer K; Shemes S; Chase P; Jose J; Johnson LB; Khatib R
J Clin Microbiol; 2009 Jun; 47(6):1640-4. PubMed ID: 19369444
[TBL] [Abstract][Full Text] [Related]
13. Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study.
Martirosov DM; Bidell MR; Pai MP; Scheetz MH; Rosenkranz SL; Faragon C; Malik M; Mendes RE; Jones RN; McNutt LA; Lodise TP
BMC Infect Dis; 2017 Aug; 17(1):534. PubMed ID: 28764660
[TBL] [Abstract][Full Text] [Related]
14. Growing Resistance to Vancomycin among Methicillin Resistant Staphylococcus Aureus Isolates from Different Clinical Samples.
Pahadi PC; Shrestha UT; Adhikari N; Shah PK; Amatya R
JNMA J Nepal Med Assoc; 2014; 52(196):977-81. PubMed ID: 26982895
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011.
Hanaki H; Cui L; Ikeda-Dantsuji Y; Nakae T; Honda J; Yanagihara K; Takesue Y; Matsumoto T; Sunakawa K; Kaku M; Tomono K; Fukuchi K; Kusachi S; Mikamo H; Takata T; Otsuka Y; Nagura O; Fujitani S; Aoki Y; Yamaguchi Y; Tateda K; Kadota J; Kohno S; Niki Y
J Infect Chemother; 2014 Sep; 20(9):527-34. PubMed ID: 25066429
[TBL] [Abstract][Full Text] [Related]
16. Detection of heterogeneous vancomycin-intermediate
Amberpet R; Sistla S; Sugumar M; Nagasundaram N; Manoharan M; Parija SC
Indian J Med Res; 2019 Aug; 150(2):194-198. PubMed ID: 31670275
[TBL] [Abstract][Full Text] [Related]
17. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin MIC susceptibility testing of methicillin-susceptible and methicillin-resistant Staphylococcus aureus isolates: a comparison between Etest® and an automated testing method.
Bland CM; Porr WH; Davis KA; Mansell KB
South Med J; 2010 Nov; 103(11):1124-8. PubMed ID: 20890258
[TBL] [Abstract][Full Text] [Related]
19. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.
Horne KC; Howden BP; Grabsch EA; Graham M; Ward PB; Xie S; Mayall BC; Johnson PD; Grayson ML
Antimicrob Agents Chemother; 2009 Aug; 53(8):3447-52. PubMed ID: 19506056
[TBL] [Abstract][Full Text] [Related]
20. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
Hidayat LK; Hsu DI; Quist R; Shriner KA; Wong-Beringer A
Arch Intern Med; 2006 Oct; 166(19):2138-44. PubMed ID: 17060545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
